Navigation Links
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
Date:6/29/2010

of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
2. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
3. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
4. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
5. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
6. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
10. AEterna Zentaris Announces Appointment of New Board Member
11. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 YourEncore, ... the life sciences, consumer products and food sciences ... and the Alliance for Clinical Research Excellence and ... system for conducting clinical research, have partnered to ... , YourEncore brings to ACRES experts ...
(Date:4/20/2015)... VANCOUVER, British Columbia and ...   DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data at the 106th Annual Meeting of ... Annual Meeting on the potential for its lead ...
(Date:4/20/2015)... Orthobiologics are substances that are ... orthobiologics market is a rewarding market, which represents a ... orthobiologics market report defines and segments the concerned market ... market was valued at $5,712.4 million in 2014, and ... a CAGR of 6.7% from 2014 to 2019. ...
(Date:4/20/2015)... CITY, Calif. , April 20, 2015 ... InterpretOmics Pvt. Ltd. to provide an integrated Big Data ... of all biomarkers collected in the context of clinical ... needs of precise or multi-targeted drug candidates, stratified patient ... and disease progression free survival. Highlighting ...
Breaking Biology Technology:YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2
... of storing electronic information from old cassette tapes ... force in the electronics industry for decades. , Low-power, ... collaborative research led by Cornell materials scientist Darrell Schlom. ... journal Science (Vol. 324 No. 5925), involves ...
... Review Services to Improve Safety and Quality of ... a leading provider of specialty healthcare solutions, and ... been selected by the New York State Department ... best practice utilization review program. The program examines ...
... Proteolix, Inc. today announced the appointment of Craig C. ... and Corporate Development and Chief Financial Officer (CFO), and ... leadership team with the appointment of Michael G. Kauffman, ... (CMO) and Albert L. Kraus, Ph.D., to the newly-created ...
Cached Biology Technology:Putting the squeeze on an old material could lead to 'instant on' electronic memory 2APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 2APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 3APS Healthcare and Thomson Reuters to Manage New York State's Medicaid Clinical Best Practices Review Program 4Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team 2Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team 3Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team 4
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... the United States should be cautious but not overly ... director at Kansas State University. Gary Anderson, director ... of the virus, which recently cropped up in the ... in the United States. "We are fortunate that ...
... School of Medicine of the University of Southern California ... & Eileen L. Norris Foundation that will be critical in ... the study of epigenetics. The grant will solidify USCs ... great promise in the treatment and prevention of cancer, says ...
... An idea Rochester Institute of Technology professor James Winebrake ... energy issues at Shenandoah National Park in Virginia has ... national parks to identify ways to make historic sites ... Winebrake recently won a $350,000 grant from the National ...
Cached Biology News:K-State Veterinary Lab routinely tests for bluetongue virus 2$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3Universities partner with national parks to give historic sites energy makeovers 2
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Biology Products: